

Dear Mr Kenneth Frazier (Chairman and CEO of Merck)

Thank you for taking time to read our letter addressing the cost of Sugammadex.

Sugammadex is a unique reversal agent that improves patient outcomes and safety.

It's cost has understandably lead institutions to limit access to it. Those institutions procuring Sugammadex at its cheapest tend to benefit from unrestricted access, while those purchasing it at its most expensive often choose not to stock it. While access limitations are made at the discretion of individual institutions, they are obliged to protect the finite health care dollar.

We would like to highlight the significant stress this cost disparity places on healthcare staff. Restriction of access risks otherwise avoidable patient morbidity and mortality.

We ask that Merck (MSD) reconsider this cost disparity so all institutions benefit from the optimal patient care afforded by unrestricted access to Sugammadex. Merck (MSD) will profit from this through increased sales, the goodwill generated and being established as a beacon of patient safety.

We look forward to your reply.

Kind Regards,

The patientsafe team

21st May 2016